Ranbaxy Laboratories’ former flagship skincare brand Sotret will soon be re-launched in the US through Cipher Pharmaceuticals, a Canada based company. The final review of the drug will be conducted on May 29, 2012 by the US drug regulator - USFDA.
Sotret along with other 30 drugs were banned in September 2008 by the USFDA for violating US drug manufacturing norms. Prior to the ban, Sotret had generated approximately $50 million in annual sales and was Ranbaxy's third best selling drug globally.
Cipher is the marketing partner for Sotret which specializes in developing improved formulations of existing drugs out-licenses them to partners for a fee.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1840.55 |
| Dr. Reddys Lab | 1276.25 |
| Cipla | 1383.75 |
| Zydus Lifesciences | 1070.00 |
| Lupin | 2363.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: